SS Innovations International Inc.

SS Innovations International Inc.

NNASDAQ:SSII
1.35
USD
-0.31
(-18.67%)
-0.06EPS
830.70MMarket Cap
SS Innovations International Inc.
NASDAQ:SSII
(Nasdaq Stock Market)

Recent

price

1.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
0.11
0.04
0.12
0.22
0.27
Revenue per Share
-0.23
-0.5
-0.46
-1.57
-0.48
-0.52
-0.25
-0.14
-0.11
-0.06
-0.06
Basic EPS, GAAP
-0.12
-0.22
-0.22
-0.22
-0.04
-0.13
-0.48
-0.11
-0.06
-0.12
-0.09
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.17
0.05
-0.11
-0.49
-0.34
0.04
-0.5
0.12
0.08
0.2
0.27
Book Value per Share
-0.19
0.03
-0.14
-0.49
-0.34
0.04
-0.5
0.12
0.08
0.2
0.27
Tangible Book Value per Share
2
2
2
2
2
3
13
145
171
190
196
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
1
6
21
42
52
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-206.01
-345.07
-91.9
-19.29
-16.18
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
Depreciation Expense
- -
-1
-1
-3
-1
-1
-3
-21
-19
-12
-12
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-223.79
-355.36
-92.74
-28.55
-23.73
Profit Margin (%)
- -
- -
- -
-1
-1
- -
-4
13
6
23
40
Working Capital
- -
- -
- -
- -
- -
- -
2
2
2
2
3
LT Debt
- -
- -
- -
-1
-1
- -
-3
20
13
38
53
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-115.45
-46.94
-26.06
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12
12
15
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
194
200
200
Market Capitalization
1,103
1,001
831

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
49
66
71
Cash, Cash Equivalents & STI
3
16
14
Accounts Receivable, Net
12
14
17
Inventories
17
17
18
Total Current Liabilities
26
26
32
Payables & Accruals
11
11
13
ST Debt
12
12
15
Deferred Revenue
3
4
4

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-559.09%
184%
Free Cash Flow
- -
426.62%
118.43%
Net Income, GAAP
- -
130.64%
-36.68%
Sales/Revenue/Turnover
- -
- -
105.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
5
4
6
21
2025
5
10
13
15
42
2026
11
14
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
-0.02
-0.02
-0.04
-0.11
2025
-0.03
- -
-0.02
-0.01
-0.06
2026
-0.02
-0.01
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
SS Innovations International, Inc. (NASDAQ: SSII) operates as a commercial-stage surgical robotics company that develops, manufactures, and markets advanced, cost-effective robotic systems and related instruments to enable minimally invasive procedures across multiple specialties. Founded in 2015 by Dr. Sudhir Srivastava and headquartered in Gurugram, India, with additional presence in Fort Lauderdale, Florida, the company offers its flagship SSi Mantra surgical robotic system, which supports validated procedures in urology such as radical prostatectomy and nephrectomy; gynecology including hysterectomy and sacrocolpopexy; cardiac surgeries like totally endoscopic coronary artery bypass; thoracic operations such as lobectomy and thymectomy; general surgery encompassing cholecystectomy and hernia repairs; gastrointestinal interventions including esophagectomy and gastrectomy; and head & neck procedures like tonsillectomy; alongside SSi Mudra endosurgical instruments comprising stapling, energy, and core tools including forceps, scissors, electrocautery, and scalpels; accessory products such as sterile drapes, 3D stereo endoscopes, cannulas, and seals; SSi Maya mixed reality training simulator; SSi Yantra multimedia recording and streaming platform; and services including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring. The company sells through direct sales and distributor networks primarily in India and internationally across seven countries with regulatory approvals, targeting hospitals and underserved populations to democratize access to robotic surgery. Recent developments include surpassing 100 SSi Mantra system installations with over 5,000 robotic surgeries performed as of mid-2025; reporting third-quarter 2025 revenue growth driven by 27 system installations, up 350% year-over-year, with nine-month revenue up 123% to $28 million; appointing Naveen Kumar Amar as Chief Financial Officer in September 2025; completing a human factors validation study at Johns Hopkins Hospital in September 2025 ahead of a planned FDA 510(k) submission in Q4 2025; pursuing U.S. and European market entry with De Novo FDA application and CE Mark expected in late 2025; and advancing pipeline technologies such as intraoperative holographic anatomy, telesurgery with 5G, and AI-assisted tools.

Company News

  • SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion

  • SS Innovations Showcases SSi Mantra Telesurgery Capabilities at October 2026 Conferences

  • SSi Falls 32% in Three Months: Should You Buy the Dip or Wait?

  • SS Innovations International (NASDAQ:SSII) Shares Gap Down – Here’s What Happened

  • SS Innovations Submits Response to FDA Request for Additional Information Regarding the Company's 510(k) Submission for the SSi Mantra

  • Comparing SS Innovations International (NASDAQ:SSII) and Terumo (OTCMKTS:TRUMY)

  • 2 International Microcaps for Your Watchlist

  • Critical Survey: OrthoPediatrics (NASDAQ:KIDS) vs. SS Innovations International (NASDAQ:SSII)

  • Zacks Initiates Coverage of SSi With Neutral Recommendation

  • SS Innovations Provides Update on Continuing Progress and Milestones

  • SS Innovations Reports Second Quarter 2026 Financial Results

  • SS Innovations To Showcase the SSi Mantra Surgical Robotic System at SRS 2026

  • SS Innovations Appoints Sarah M. Romano as Chief Financial Officer

  • SS Innovations Subsidiary SSICRS Graduates Inaugural Cardiac Robotic Surgery Training Class

  • IBN Initiates Coverage of SS Innovations International, Inc.

  • SS Innovations Named Outstanding Company Winner at the 2026 Surgical Robotics Industry Awards

  • SS Innovations Named Outstanding Company Winner at the 2026 Surgical Robotics Industry Awards

  • SS Innovations' Surgical Robotics Expansion Continues As Revenue More Than Doubles

  • SS Innovations Announces Completion of World's Longest-Distance Robotic Telesurgery

  • SS Innovations Announces Completion of World's Longest-Distance Robotic Telesurgery